CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed
Drug / intervention
Galantaminedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00164242
NCT00164242Phase 4Completed
CompareCT.gov

Treatment of Tardive Dyskinesia With Galantamine

Caroff, Stanley N., M.D.·interventional·Posted Sep 14, 2005·Updated Sep 14, 2005

In Brief

A Phase 4 clinical trial evaluating Galantamine for Tardive Dyskinesia. Completed, across 1 site.

Detailed Summary

Tardive dyskinesia (TD), a form of movement disorder, remains a problem for some patients who received antipsychotic medications. Increasing evidence suggests that TD may result from antipsychotic-induced dysfunction in striatal cholinergic neurons. To test whether cholinesterase inhibitors compensate for diminished cholinergic activity underlying TD, we conducted a 30-week randomized, double-blind, placebo-controlled crossover study of galantamine in 36 patients with TD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTardive Dyskinesia
CountriesUnited States
CollaboratorsOrtho-McNeil Neurologics, Inc.

Timeline

Phase 4CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 14, 2005
Enrollment StartJan 1, 2002
Study CompletionOct 1, 2004
TodayJul 2, 2026
Posted 20.8 years ago

Interventions

Galantaminedrug